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Abstract
PURPOSE: Angiogenesis plays an important role in pancreas cancer pathobiology. Pancreatic tumor cells secrete
vascular endothelial growth factor (VEGF), activating endothelial cell protein kinase C beta (PKCβ) that phosphory-
lates GSK3β to suppress apoptosis and promote endothelial cell proliferation and microvessel formation. We used
Enzastaurin (Enz) to test the hypothesis that inhibition of PKCβ results in radiosensitization of endothelial cells in
culture and in vivo. MATERIALS/METHODS: We measured PKCβ phosphorylation, VEGF pathway signaling, colony
formation, and capillary sprout formation in primary human dermal microvessel endothelial cells (HDMECs) after
Enz or radiation (RT) treatment. Microvessel density and tumor volume of human pancreatic cancer xenografts in
nude mice were measured after treatment with Enz, RT, or both. RESULTS: Enz inhibited PKCβ and radiosensitized
HDMEC with an enhancement ratio of 1.31 ± 0.05. Enz combined with RT reduced HDMEC capillary sprouting to a
greater extent than either agent alone. Enz prevented radiation-induced GSK3β phosphorylation of serine 9 while
having no direct effect on VEGFR phosphorylation. Treatment of xenografts with Enz and radiation produced greater
reductions in microvessel density than either treatment alone. The reduction in microvessel density corresponded
with increased tumor growth delay. CONCLUSIONS: Enz-induced PKCβ inhibition radiosensitizes human endothelial
cells and enhances the antiangiogenic effects of RT. The combination of Enz and RT reduced microvessel density
and resulted in increased growth delay in pancreatic cancer xenografts, without increase in toxicity. These results
provide the rationale for combining PKCβ inhibition with radiation and further investigating such regimens in pancre-
atic cancer.
Translational Oncology (2008) 1, 195–201
Introduction
Aberrant activation of protein kinase Cβ (PKCβ), an intracellular serine/
threonine kinase, promotes endothelial cell proliferation and tumor-
directed angiogenesis [1]. Tumor cells secrete vascular endothelial
growth factor (VEGF) that binds to VEGFR2 on endothelial cells,
resulting in the activation of PKCβ by phosphorylation at threonine
500 [1]. Active PKCβ leads to increased survival and proliferation
signals, such as phosphorylation of GSK3β at serine 9 [2–4]. Thus,
PKCβ inhibition could prevent tumor recruitment of endothelial cells
and increase the effect of agents that cause endothelial cell death.
Pancreatic cancers have high microvessel density that correlates
with shorter overall survival time [5], higher rates of liver metastasis,
and worse prognosis [6]. Paradoxically, the microvessel density does
not lead to higher perfusion, as the pathologic angiogenesis is as-
sociated with increased vascular permeability. The resulting high
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interstitial pressure and hypoxia [7] may contribute to the clinically
observed radioresistance. Pancreatic cancers also express PKCβ at
higher levels compared with surrounding tissue [8]. Interrupting
tumor-mediated recruitment of blood vessels could reverse the hy-
perpermeable state of pancreatic tumor blood supply, and the resto-
ration of normoxia could enhance the cytotoxic effects of radiation,
providing rationale for the inhibition of PKCβ concurrent with radia-
tion in pancreatic tumors.
Enzastaurin (Enz) is a potent and selective inhibitor of PKCβ with
antiproliferative activity [inhibitory concentration of 50% (IC50)
∼6 nM]. Enz suppresses VEGF-induced angiogenesis in the rat cor-
neal micropocket assay, decreases microvessel density, and prevents
VEGF secretion from human tumor cell xenografts in nude mice
[9]. Prolonged courses of Enz increase chemotherapy or radiation
tumor growth delay of glioma, breast, and small cell lung cancer
xenografts [10]. We demonstrated that inhibition of PKCβ with
enzastaurin provides modest radiosensitization of pancreatic cancer
cells in culture, with increased magnitude of radiosensitization of
pancreatic cancer cell xenografts [11]. Enz has been well tolerated
in phase 1 and 2 clinical trials, both as monotherapy and in com-
bination with chemotherapy [12]. However, Enz and radiation have
not been combined in a prospective clinical trial, and preclinical stud-
ies examining their interaction could lead to a novel trial.
Therefore, we tested the hypothesis that inhibition of PKCβ with
Enz would radiosensitize endothelial cells and would enhance the
antiangiogenic effects of radiation. We first tested whether Enz could
inhibit PKCβ in primary endothelial cells at concentrations similar
to those attainable in patients and determined the specificity of
Enz. We then used an in vitro model of endothelial cell sprouting
to assess the effect of Enz and radiation on precursors to intact vas-
culature. Finally, we tested our hypothesis in vivo using nude mice
bearing pancreatic cancer cell xenografts treated with radiation alone,
Enz alone, or the combination, using tumor size and microvessel
density as end points to determine efficacy.
Materials and Methods
Cell Lines
Primary human dermal endothelial cells (HDMECs) were obtained
from Clonetics (East Rutherford, NJ) and were maintained in EGM-
2MV supplemented with 50 ng/ml rhVEGF165 as per the manufac-
turer’s instructions. Panc-1 and BxPC3 human pancreatic cancer cells
were obtained from the American Type Culture Collection (Manassas,
VA) and were maintained in Roswell Park Memorial Institute (RPMI)
medium containing 10% bovine serum in an atmosphere of 93% air
and 7% carbon dioxide.
Colony Formation Assays
After Enz treatment or irradiation, HDMECs were trypsinized,
counted, and plated at clonal densities. Fourteen days later, cells were
fixed and stained with crystal violet, as previously published by others
[13]. Colony counting was done using an automated counter. The
mean inactivation dose (MID) [14] was calculated for control and
each dose of Enz, and the enhancement ratio (ER) was calculated
as the MID in the control curve divided by the MID in the Enz
curve. The ERs shown are the average of three independent experi-
ments done in triplicate.
Capillary Sprouting
To investigate the effect of Enz on the angiogenic potential of pri-
mary endothelial cells, a capillary sprouting assay was done as de-
scribed previously [15]. Briefly, six-well plates were precoated with
1.5 mL/well Vitrogen 100 collagen (Angiotech BioMaterials, Palo
Alto, CA). Human dermal microvessel endothelial cells (5 × 105)
were added to each well and allowed to adhere overnight. Cells were
treated daily with 50 ng/mL rhVEGF165 in fresh medium until cells
were treated as described in the figure legends. Numbers of sprouts
were assessed daily with a phase microscope at an original magnifi-
cation of ×200. Six high-power fields were analyzed per well with
triplicate wells per treatment, and a minimum of three independent
experiments were conducted.
Antibodies and Immunoblot Analysis
Antibodies to PKCβ (Santa Cruz Biotechnology, Santa Cruz, CA),
phosphoThr500 PKCβ (Abcam, Cambridge, MA), GSK3β (Cell
Signaling, Danvers, MA), phosphoSer21GSK3α/Ser9GSK3β (Cell
Signaling), VEGFR2 (Cell Signaling), phosphoTyr951 VEGFR2
(Cell Signaling), p42/44 mitogen-activated protein kinase (MAPK;
Cell Signaling), and phosphoThr202/Tyr204 p42/44 MAPK (Cell
Signaling) were used at dilutions recommended by the manufacturer.
Cell lysate production with RIPA buffer and immunoblot analysis
were performed using detailed protocols from Cell Signaling. Protein
concentrations were determined with BCA Protein Assay (Pierce,
Rockford, IL), and 10 μg of protein was loaded in each lane. Each
experiment was conducted a minimum of three independent times.
Immunohistochemistry
We determined that five 2-Gy fractions in Panc1 xenografts pro-
duced similar tumor growth delay as ten 2-Gy fractions in BxPC3
xenografts [11]. To compare the effects of enzastaurin on biologically
similar end points, we used 5 fractions in the Panc1 experiments and
10 fractions in the BxPC3 experiments. Enzastaurin was given twice
daily concurrently with radiation. Xenografts were collected on the
last day of treatment for each group and placed in formalin overnight
followed by 70% ethanol. Samples were embedded in paraffin, and
immunohistochemistry was performed with anti-CD31 for micro-
vessel density (MVD) by the immunohistochemistry core at the
University of Michigan. To determine MVD, the slides were blinded
to the counter, and the number of patent vessels was scored in 10
high-powered (×400) fields.
Xenografts
Animals used in this study were maintained in facilities approved
by the American Association for Accreditation of Laboratory Ani-
mal Care in accordance with current regulations and standards of
the United States Department of Agriculture and Department of
Health and Human Services. Under an institutionally approved pro-
tocol, 4-week-old female athymic nude mice were implanted with
5 × 107 BxPC3 or Panc1 cells subcutaneously. Tumor volume
(TV) was calculated according to the following equation: TV =
π/6 × a × b2, where a and b are the longer and shorter dimensions
of the tumor, respectively. When the average tumor volume achieved
100mm3, mice were randomized to treatment groups of vehicle alone,
Enz (100-mg/kg gavage twice daily) alone, radiation alone, or Enz with
radiation. This dose of Enz produces similar serum concentrations to
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those achieved in patients from phase 1 trials, approximately 1 μM
[16]. Radiation was given 3 to 4 hours after Enz, corresponding to
the maximum amount of GSK3β dephosphorylation seen in mouse
xenografts [16]. Data are expressed as the ratio of TV at varying times
after treatment compared to the day of irradiation (Day 0). The abso-
lute and normalized growth delays were calculated to compare the ef-
ficacy of each regimen. Absolute growth delay is defined as the time in
days for tumors in the treatment arms to quadruple their volume mi-
nus the time in days for the tumors in the untreated control group to
reach the same size. Normalized growth delay is defined as the time for
tumors in groups treated with a combined regimen to quadruple their
volume minus the time to reach the same size in mice treated with Enz
alone [17].
Irradiation
Cells or xenografts were irradiated using a Phillips 250 orthovolt-
age unit (Phillips, Bothell, WA) at approximately 2 Gy/min for cells
or 1.4 Gy/min for mice in the Irradiation Core of the University of
Michigan Cancer Center. Dosimetry was carried out using an ioniza-
tion chamber connected to an electrometer system, which is directly
traceable to a National Institute of Standards and Technology calibra-
tion. Mice were anesthetized with a mixture of 60-mg/kg ketamine
and 3-mg/kg xylazine and were positioned such that the apex of each
f lank tumor was at the center of a 2.4-cm aperture in the secondary
collimator and irradiated with the rest of the mouse being shielded
from radiation.
Statistical Analysis
Differences between groups in microvessel density, tumor size, or
mean growth delay were tested for significance with an unpaired,
2-tailed, Student’s t test. Analysis of variance was used for simulta-
neous multiple comparisons across more than two treatment arms.
The xenograft studies were powered at 80% to detect a 30% differ-
ence in absolute growth delay between the combination treatment
arm and control.
Results
We tested the effects of radiation and Enz on PKCβ activity by
immunoblot analysis for phosphorylated PKCβ. Active PKCβ can
phosphorylate GSK3β at serine 9, and others have shown that radia-
tion induces GSK3β serine 9 phosphorylation in endothelial cells
[18]. We tested whether radiation or Enz treatment affected GSK3β
serine 9 phosphorylation. Primary human endothelial cells were
treated with radiation with or without pretreatment with 1 μM Enz
for 24 hours. Radiation induced phosphorylation of threonine 500,
consistent with activation of PKCβ in a dose-dependent manner
(Figure 1A). Similarly, radiation induced the phosphorylation of
GSK3β serine 9 (Figure 1B). Pretreatment for 24 hours with 1 μM
Enz prevented radiation-induced PKCβ T500 phosphorylation
and GSK3β serine 9 phosphorylation. Total levels of PKCβ and
GSK3β were unchanged. In primary endothelial cells grown in cul-
ture, Enz inhibited radiation-induced PKCβ activation and GSK3β
serine 9 phosphorylation.
We next assessed the effect of Enz on radiation cytotoxicity in
endothelial cells by colony formation in culture. Primary human
endothelial cells in log-phase growth were treated with incremental
doses of radiation with or without pretreatment with 1 μM Enz
for 24 hours (Figure 2A), resulting in decreased clonogenic survival
with Enz (P < .05). Enz produced an ER of 1.31 ± 0.05 (n = 3) in
primary endothelial cells. These data indicate that Enz modestly radio-
sensitizes primary endothelial cells grown in culture.
We next conducted experiments to determine the ability of Enz,
radiation, or the combination to influence primary endothelial cell
formation of capillary sprouts in culture. Human dermal microvessel
endothelial cells treated with daily Enz alone had significantly reduced
capillary sprout formation (Figure 3A) relative to vehicle-treated wells
after 2 days (32 ± 4 vs 45 ± 3 sprouts, P < .01) and persisted through
6 days of treatment (38 ± 3 vs 55 ± 4 sprouts, P < .01, n = 3). We
conducted a dose-response experiment with single-fraction radiation
to determine the IC50 dose of radiation to combine with Enz (Fig-
ure 3B), as radiation has not been previously used in this model.
Human dermal microvessel endothelial cells treated with 0.5 Gy were
able to achieve maximum sprout formation at day 8 (84 ± 2 sprouts).
Primary endothelial cells treated with radiation had reduced capillary
sprout formation relative to control (64 ± 4 for 1 Gy vs 35 ± 2 for
2 Gy vs 32 ± 3 for 5 Gy vs 82 ± 4 sprouts for control, respectively,
Figure 1. Enzastaurin prevents PKCβ T500 phosphorylation and
GSKβ S9 phosphorylation in irradiated primary endothelial cells.
Human dermal microvessel endothelial cells were treated with
vehicle or 1 μM Enz for 24 hours and then exposed to 0, 2, 4, or
6 Gy. (A) Western blot analysis for total or phosphoT500 PKCβ
was performed. (B) Western blot analysis for total (bottom row)
or phosphoS9 (top row) GSKβ was performed.
Figure 2. Brief course of Enzastaurin increases radiation cytotoxicity
of primary endothelial cells. Human dermal microvessel endothelial
cells were treated with vehicle or 1 μM Enz for 24 hours and then
exposed to 0, 2, 4, 6 or 8 Gy. Colony formation was assessed per
the Materials and Methods section.
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P < .001 for all groups vs control, n = 3). Both 2 and 5 Gy virtually
eliminated the ability of HDMEC to form capillary sprouts during the
8 days. We proceeded with a single 1-Gy fraction to combine with
Enz, because either radioprotection or radiosensitization could be
demonstrated with this dose.
We also determined the effect of 1 Gy with Enz on VEGFR sig-
naling. As shown in Figure 4A, 1 μM Enz inhibited both PKCβ and
GSKβ phosphorylation. To assess the specificity of Enz, we also as-
sessed VEGFR2, the receptor for VEGF, and p42/44 MAPK, a par-
allel intracellular kinase important VEGF-mediated for angiogenesis
[19,20], levels by Western blot analysis. As shown in Figure 4B, Enz
treatment did not change VEGFR or p42/44 MAPK phosphoryla-
tion, suggesting that Enz under these conditions does not change
VEGFR activation or p42/44 MAPK phosphorylation.
As shown in Figure 4, C and D, the combination of 1 μM Enz with
1-Gy radiation resulted in greater reduction in capillary sprout forma-
tion than either agent alone (34 ± 4 sprouts with combination vs 93 ±
9 for Enz vs 73 ± 4 for 1 Gy vs 110 ± 4 for control, P < .001 for
all groups vs combination, n = 3). Similar results were achieved with
0.3 μM Enz and 1 Gy (Figure W1). These experiments demonstrate
that Enz and radiation in combination inhibit capillary sprout forma-
tion on a collagen matrix to a greater extent than either agent alone.
We next conducted experiments to determine the effect of enzastaurin
on pancreatic cancer cells on endothelial cell VEGFR2 signaling, be-
cause pancreatic cancer cells can secrete VEGF to promote angio-
genesis [21–23]. Conditioned medium from BxPC3 and Panc1
cells induced VEGFR2 phosphorylation, which was not affected by
Enz (Figure 5). However, Enz did prevent the GSK3β phosphoryla-
tion that occurred after exposure to conditioned medium. These
results are consistent with Enz preventing pancreatic cancer cell angio-
genic signals downstream of VEGFR2.
Given the results with primary endothelial cells in culture, we
sought to determine the ability of Enz, radiation, and the combina-
tion to reduce microvessel density of pancreatic cancer cell xeno-
grafts. Nude mice bearing either Panc1 or BxPC3 xenografts were
treated with vehicle, Enz, five 2-Gy fractions to the tumor, or con-
current Enz and radiation (Figure 6). Untreated Panc1 tumors had
a microvessel density of 15 ± 1, whereas BxPC3 cells had 21 ± 1 ves-
sel per high-powered field. Treatment of Panc1 and BxPC3 xeno-
grafts with Enz and radiation reduced microvessel density greater
than either treatment alone (MVD ± SD): 3 ± 1 and 8 ± 1 for RT
with Enz, 10 ± 1 and 13 ± 1 for RT alone, and 8 ± 1 and 19 ± 8 for
Enz alone (P < .01 between combination vs other arms), respectively.
There was no difference in TUNEL-positive cells between any of
the treatment arms (Figure W2). These xenograft experiments are
consistent with the primary endothelial microvessel formation experi-
ments demonstrating that the combination of Enz and radiation dis-
rupt vasculature greater than either alone.
To determine whether the reductions in microvessel density re-
sulted in prolonged tumor growth delay, a larger experiment was con-
ducted with BxPC3 xenograft bearing mice. Mice were treated with
vehicle alone, Enz, five 2-Gy fractions to the tumor, or Enz and five
2-Gy fractions (Figure 6C ). The combination of Enz with radiation
had decreased tumor volume compared to the other treatment arms
by day 15 (248 ± 61 mm3 for control vs 346 ± 43 mm3 for Enz alone
vs 257 ± 41 for radiation alone vs 160 ± 30 for combination, P < .03
for combination vs other groups, n = 16 tumors). The combination
arm resulted in prolonged absolute tumor growth delay (5.6 days),
whereas those treated with either Enz (0.1 days) or radiation alone
(0.3 days) did not demonstrate significant growth delay. This resulted
in a normalized growth delay of 5.5 days. Thus, in this model of ag-
gressive pancreatic cancer, neither Enz nor radiation alone produced
effective tumor growth delay, whereas the combination had efficacy.
Discussion
We tested the hypothesis that inhibition of PKCβ with Enz po-
tentiates the antivascular and cytotoxic effects of radiation on endo-
thelial cells in culture and in vivo. We found that Enz inhibits PKCβ
and phosphorylation of its downstream target GSKβ in primary en-
dothelial cells at concentrations similar to those achieved in patients.
In a model of endothelial cell sprouting, we found that Enz and
radiation together had a larger effect than either alone on precursors
to intact vasculature. Pancreatic cancer cell xenografts treated with
the combination of radiation and Enz had decreased microvessel den-
sity with corresponding increased tumor growth delay compared to
either agent alone. Taken together, these data provide evidence that
Figure 3. Prolonged enzastaurin treatment or higher doses of RT
reduce endothelial cell capillary sprout formation. (A) Human der-
mal microvessel endothelial cells formation of capillary sprouts on
a collagen matrix treated with vehicle (open circles) or daily 1 μM
Enz (black triangles). (B) Human dermal microvessel endothelial
cells formation of capillary sprouts on a collagen matrix treated
with vehicle (open circles), 0.5 Gy (black circles), 1 Gy (black
squares), 2 Gy (black diamonds), or 5 Gy (black X). The values
displayed represent mean ± SE of two independent experiments
performed in triplicate. *P < .05 between control and indicated
radiation dose.
198 PKCβ Inhibition Radiosensitizes Vasculature Spalding et al. Translational Oncology Vol. 1, No. 4, 2008
inhibition of PKCβ with Enz radiosensitizes endothelial cells in cul-
ture and in vivo, suggesting this approach may improve radiation
response of tumors through antivascular effects.
Protein kinase C inhibition alone or in combination with radiation
has efficacy in preclinical models of cancer. Protein kinase C β pro-
motes colon [24] and breast [25] cancer cell cycle progression. Tar-
geted silencing of PKCβ or pharmacologic inhibition has been shown
to inhibit proliferation in culture of colon, glioma, breast, and ovar-
ian cancer cells. Others have shown that pharmacologic agents that
inhibit PKC isoforms can radiosensitize cancer cells in culture and
in vivo [4,26]. Our results also are consistent with and build on these
previously published works by focusing on the effect of PKCβ inhi-
bition and radiation in endothelial cells.
Tumor response to radiotherapy can be improved by targeting an-
giogenesis signaling pathways [27–29]. The underlying mechanisms
are not fully understood, but it has been suggested that induction of
VEGF by radiation [27] may contribute to radioresistance by pro-
moting survival of endothelial cells in tumor vasculature. Other pro-
angiogenic growth factors, including fibroblast growth factor and
platelet derived growth factor [30,31], are also known to be up-
regulated by radiation and may play similar role. In addition, tumor
oxygenation, critical to the efficacy of radiation, has been shown to
improve during VEGFR2 blockade [32]. Enz is a potent and selec-
tive inhibitor of PKCβ, a predominant mediator of VEGF-induced
endothelial cell proliferation and survival [33,34]. Thus, it is possible
that Enz could enhance radiation cytotoxicity of tumors through its
antivascular effects.
A body of evidence points to the importance of PKCβ-dependent
angiogenesis in pancreas cancer. Protein kinase C β is overexpressed
in pancreatic cancer relative to surrounding stroma [8], and VEGFR
activation leads to PKCβ-dependent endothelial cell proliferation [1].
Figure 4. Brief course of enzastaurin potentiates the antivascular effects of 1-Gy radiation. Human dermal microvessel endothelial cells
were treated with vehicle or 1 μM Enz for 24 hours and then exposed to 0 or 1 Gy. Western blot analysis of phosphorylated and total
PKCβ and GSK3β (A) or p42/44 MAPK and VEGFR2 (B) was performed. (C) Human dermal microvessel endothelial cells formation of
capillary sprouts on a collagen matrix treated with vehicle (open circles), 1 Gy (black squares), 1 μM Enz for 48 hours (black triangles), or
1 Gy in the middle of 1 μM Enz for 48 hours (black +). Mean values of three independent experiments performed in triplicate ± SEM are
displayed. *P < .05 between combination arm and control or single agent arms. (D) Representative images of HDMEC at day 7 from B.
Figure 5. Effect of pancreatic cancer secretions on endothelial cell
VEGFR signaling. Human dermal microvessel endothelial cells were
treated with control medium (HD), medium from BxPC3 cells (Bx),
or medium from Panc1 cells (P1), with or without enzastaurin. West-
ern blot analysis of phosphorylated and total VEGFR2 and GSK3β
was performed.
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Both VEGF [21–23] and VEGF receptors [35] are overexpressed
in pancreatic cancer. Vascular endothelial growth factor promotes
pancreatic cancer growth through a paracrine and/or autocrine mech-
anism [22,35,36] and that VEGFR promotes migration [37], inva-
sion, and mesenchymal transition [38] in pancreatic carcinoma cell
lines. Finally, high VEGF expression correlates with microvessel den-
sity and with poor prognosis [21–23] in patients.
There are limitations to our study. We have attempted to study the
effects of Enz and radiation on endothelial cell survival and ability
to form blood vessels. The sprouting of endothelial cells on a bed
of collagen occurs for several days, allowing for migration and pro-
liferation contributions to angiogenesis. This model is ideal for de-
termining doses and schedules of radiation and systemic agents, but
nonetheless, it must be tested in vivo. Our xenograft model of pancre-
atic cancer has the limitations of mouse vasculature with human tumor
cells. It is likely that tumors that arise de novo in patients have different
mechanisms for endothelial cell recruitment. Despite these limitations,
our studies give merit to inhibition of PKCβ-dependent angiogenesis
with radiation in the treatment of cancer.
In summary, our results support the use of Enz with radiation to
target endothelium. Tumor-induced angiogenesis requires activation
of the PKCs, particularly PKCβ [39], and Enz is a potent and selec-
tive inhibitor of PKCβ. Thus, the rationale for antiangiogenic therapy
through PKCβ inhibition in pancreas cancer is solid. A natural exten-
sion of these studies would be to investigate the effects of Enz, radia-
tion, and cytotoxic chemotherapeutic agents used in the treatment of
pancreatic cancer such as gemcitabine and 5-fluorouracil on endothe-
lial cells. Our results suggest that regimens combining PKCβ inhibi-
tion with radiation might be worthwhile investigating in clinical trials.
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Figure W1. Human dermal microvessel endothelial cell formation
of capillary sprouts on a collagen matrix treated with vehicle (open
circles), 1 Gy (red squares), 0.3 μM Enz for 48 hours (black circles),
or 1 Gy in the middle of 0.3 mM Enz for 48 hours (blue triangles).
Mean values of three independent experiments performed in trip-
licate ± SEM are displayed. *P < .05 between combination arm
and control or single agent arms.
Figure W2. Nude mice bearing BxPC3 or Panc1 xenografts were treated with vehicle, Enz 100 mg/kg twice daily, 2 Gy once daily, or
Enz and radiation. At least four tumors were collected immediately after the last treatment rendered and were stained for TUNEL. P =
NS between combination arm and individual treatment arms.
